The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

Chronic kidney disease is a progressive disease with no cure and high morbidity and
mortality that occurs commonly in the general adult population, especially in people with …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for
treatment of diabetes, have been shown to possess a favorable metabolic profile and to …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Kidney size and glomerular filtration rate (GFR) often increase with the onset of diabetes,
and elevated GFR is a risk factor for the development of diabetic kidney disease …

Summary Background In the Canagliflozin Cardiovascular Assessment Study (CANVAS)
Program, canagliflozin reduced the rates of major adverse cardiovascular events and the …

Numerous studies have indicated that the progression of chronic kidney disease (CKD) to
end-stage renal disease (ESRD) is strictly associated with the accumulation of toxic …